352 related articles for article (PubMed ID: 35194830)
1. Rapid and efficient generation of antigen-specific isogenic T cells from cryopreserved blood samples.
Eerkens AL; Vledder A; van Rooij N; Foijer F; Nijman HW; de Bruyn M
Immunol Cell Biol; 2022 Apr; 100(4):285-295. PubMed ID: 35194830
[TBL] [Abstract][Full Text] [Related]
2. Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies.
Nüssing S; House IG; Kearney CJ; Chen AXY; Vervoort SJ; Beavis PA; Oliaro J; Johnstone RW; Trapani JA; Parish IA
J Immunol; 2020 Apr; 204(8):2308-2315. PubMed ID: 32152070
[TBL] [Abstract][Full Text] [Related]
3. Primary Airway Epithelial Cell Gene Editing Using CRISPR-Cas9.
Everman JL; Rios C; Seibold MA
Methods Mol Biol; 2018; 1706():267-292. PubMed ID: 29423804
[TBL] [Abstract][Full Text] [Related]
4. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells.
Kamali E; Rahbarizadeh F; Hojati Z; Frödin M
BMC Biotechnol; 2021 Jan; 21(1):9. PubMed ID: 33514392
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
7. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of mouse and human preimplantation development following POU5F1 CRISPR/Cas9 targeting reveals interspecies differences.
Stamatiadis P; Boel A; Cosemans G; Popovic M; Bekaert B; Guggilla R; Tang M; De Sutter P; Van Nieuwerburgh F; Menten B; Stoop D; Chuva de Sousa Lopes SM; Coucke P; Heindryckx B
Hum Reprod; 2021 Apr; 36(5):1242-1252. PubMed ID: 33609360
[TBL] [Abstract][Full Text] [Related]
10. Livestock Gene Editing by One-step Embryo Manipulation.
Navarro-Serna S; Vilarino M; Park I; Gadea J; Ross PJ
J Equine Vet Sci; 2020 Jun; 89():103025. PubMed ID: 32563448
[TBL] [Abstract][Full Text] [Related]
11. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
Tapscott T; Guarnieri MT; Henard CA
Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications.
Li Y; Glass Z; Huang M; Chen ZY; Xu Q
Biomaterials; 2020 Mar; 234():119711. PubMed ID: 31945616
[TBL] [Abstract][Full Text] [Related]
13. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Lu Y; Xue J; Deng T; Zhou X; Yu K; Deng L; Huang M; Yi X; Liang M; Wang Y; Shen H; Tong R; Wang W; Li L; Song J; Li J; Su X; Ding Z; Gong Y; Zhu J; Wang Y; Zou B; Zhang Y; Li Y; Zhou L; Liu Y; Yu M; Wang Y; Zhang X; Yin L; Xia X; Zeng Y; Zhou Q; Ying B; Chen C; Wei Y; Li W; Mok T
Nat Med; 2020 May; 26(5):732-740. PubMed ID: 32341578
[TBL] [Abstract][Full Text] [Related]
14. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
15. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
Jensen TI; Axelgaard E; Bak RO
Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
[TBL] [Abstract][Full Text] [Related]
17. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
Ebrahimi V; Hashemi A
Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-Mediated Genome Engineering of Primary Human B Cells.
Laoharawee K; Johnson MJ; Moriarity BS
Methods Mol Biol; 2020; 2115():435-444. PubMed ID: 32006415
[TBL] [Abstract][Full Text] [Related]
20. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells.
Seki A; Rutz S
J Exp Med; 2018 Mar; 215(3):985-997. PubMed ID: 29436394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
